Raymond James Financial
NERV icon

Raymond James Financial’s Minerva Neurosciences NERV Stock Holding History

Raymond James Financial’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25
Closed -$43 – 6094
2025
Q2 		$43 Buy
+25
New +$41 ﹤0.01% 6894

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial's NERV Position: Q3 2025 in Review

Raymond James Financial sold out of Minerva Neurosciences (NERV) in Q3 2025, closing a stake of 25 shares — an estimated $43 sold.

Raymond James Financial first reported a position in NERV in Q2 2025 and held it in 1 quarter. The position peaked at $43 in Q2 2025. 24 funds tracked by Wall St. Rank hold NERV as of Q3 2025.

  • Raymond James Financial reported no remaining Minerva Neurosciences position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 25 Minerva Neurosciences shares in Q3 2025, an estimated $43.
  • Raymond James Financial first reported a position in Minerva Neurosciences in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Minerva Neurosciences position peaked at $43 in Q2 2025.
  • 24 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.